Authors

Latest:

Fellows Can Join the Fight Against Cancer Misinformation Online

Many cancer organizations across the United States and internationally acknowledge a need for in-novative uses of social technology to improve cancer-related support and information provision.

Jiahn Choi, PhD

Latest:

The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality

One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.

Nathan Bahary, MD, PhD

Latest:

Dr. Bahary on the Benefits of Ivosidenib in IDH1-Mutated Cholangiocarcinoma

Nathan Bahary, MD, PhD, discusses the benefits of ivosidenib in patients with intrahepatic cholangiocarcinoma whose tumors harbor IDH1 mutations.

Kimberly Cannavale, MPH

Latest:

Cannavale on the Importance of Assessing Comorbidities and Remission Rates in Ovarian Cancer

Kimberly Cannavale, MPH, discusses the clinical implications of a study on the impact of pre-existing comorbidities on remission rates in ovarian cancer.

Andrea Facciabene, PhD

Latest:

Dr. Facciabene on Radiation Bridging Therapy Prior to CAR T-Cell Therapy in Mice Models

Andrea Facciabene, PhD, discusses investigating the use of bridging radiation therapy prior to CAR T-cell therapy in mice models.

Daniel Carrizosa, MD, MS

Latest:

Dr. Carrizosa on the Prevalence of NRG1 Gene Fusions in Solid Tumors

Daniel Carrizosa, MD, MS, discusses the prevalence of NRG1 gene fusions in solid tumors.

Alexis LeVee, MD

Alexis LeVee, MD, is chief Hematology & Medical Oncology fellow at City of Hope

Latest:

Defining HER2-Low and -Ultralow Expression: Practical Challenges and Solutions

Panelists discuss how HER2 testing challenges for identifying HER2-low and -ultralow expression require coordination with pathologists and may involve

Sarki A. Abdulkadir, MD, PhD

Latest:

Dr. Abdulkadir on the Challenges of Targeting MYC in Prostate Cancer

Sarki A. Abdulkadir, MD, PhD, discusses the challenges of targeting MYC in prostate cancer.

Costanza Lo Cascio, PhD

Latest:

A New Take on Preclinical Drug Trials for GBM Treatment

The Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix, Arizona, is attempting to subvert this pattern of clinical failure for promising therapeutics by changing the way preclinical studies are developed and conducted to assess the efficacy of drugs for GBM.

Anita Johnson, MD, FACS

Latest:

Dr. Johnson on Racial Disparities in Outcomes Across Multiple Tumor Types

Anita Johnson, MD, FACS, discusses racial disparities in outcomes across multiple tumor types.

Krish Patel, MD, Swedish Cancer Institute

Latest:

Novel Therapies for R/R Follicular Lymphoma

A panel of hematologists/oncologists remark on the transformations occurring in relapsed/refractory follicular lymphoma as newer, novel therapies continue to emerge.

Efstathios Kastritis, MD

Latest:

Dr Kastritis on the Investigation of Birtamimab in Mayo Stage IV AL Amyloidosis

Efstathios Kastritis, MD, discusses the background of birtamimab and the rationale for investigating the agent in combination with standard-of-care chemotherapy in newly diagnosed patients with Mayo Stage IV amyloid light chain amyloidosis in the phase 3 AFFIRM-AL trial.

Aimaz Afrough, MD

Latest:

Bispecific Antibodies for the Treatment of RRMM in the Post CAR T Setting

Panelists discuss how the transition from chimeric antigen receptor T-cell therapy (CAR T) to bispecific antibodies depends on disease progression and clinical status, with the choice of bispecific antibody being guided by prior therapy and target antigen, preferring B-cell maturation antigen (BCMA) bispecifics for BCMA-exposed patients and GPRC5D bispecifics for those with BCMA-relapsed disease.

Timothy I Shaw, PhD

Latest:

Dr Shaw on the Heterogeneity Between Paired Primary and Metastatic Solid Tumors

Timothy I Shaw, PhD, discusses the genetic heterogeneity between paired primary and metastatic solid tumors, as well as the implications for neoantigen-based personalized vaccines in cancer care.

Ethan B. Ludmir, MD,

Latest:

Dr Ludmir on the Rationale For the EXTEND Trial in PDAC

Ethan B. Ludmir, MD, shares the rationale for and the outcomes derived from the EXTEND trial in oligometastatic pancreatic ductal adenocarcinoma.

Yousef Zakharia, MD

Latest:

Dr Zakharia on Long-Term Benefit With Nivolumab Plus Ipilimumab in ccRCC

Yousef Zakharia, MD, discusses the long-term benefits of nivolumab plus ipilimumab according to risk status in clear cell renal cell carcinoma.

Nicholas J. Short, MD

Latest:

Understanding How to Best Measure MRD Negativity in Ph+ ALL

The implementation of treatment with later-generation BCR-ABL1 TKIs like ponatinib and chemotherapy-free combination regimens with blinatumomab plus a TKI have greatly pushed the treatment armamentarium of Philadelphia chromosome–positive acute lymphoblastic leukemia forward.

Ali R. Khaki, MD

Latest:

Optimizing Therapy for Patients with Advanced Bladder Cancer

Ali R. Khaki, MD, comments on how to treat patients with advanced bladder cancer based on data demonstrated by the EV-103 study of enfortumab vedotin.

Jennifer A. Ligibel, MD

Latest:

Slow Burn to Wildfire: How Do We Douse the Flames of Burnout in Oncology?

Trauma and stress related to the COVID-19 pandemic, coupled with subsequent widespread labor shortages, have turned burnout, which was an endemic issue in medicine, to a pandemic in health care.

Jatinder Lamba, PhD, MSc

Latest:

Dr Lamba on Rapid Long-Read Epigenomic Diagnosis and Prognosis in AML

Jatinder Lamba, PhD, MSc, discusses the potential clinical application of rapid long-read sequencing for the diagnosis of acute myeloid leukemia.